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Background: Recently we identified a relationship between human cytomegalovirus (hCMV) and human salivary
gland (SG) mucoepidermoid carcinoma (MEC) in over 90% of cases; tumorigenesis in these cases uniformly
correlated with active hCMV protein expression and an upregulation of the EGFR → ERK pathway. Our previously
characterized, novel mouse organ culture model of mouse CMV (mCMV)-induced tumorigenesis displays a number
of histologic and molecular characteristics similar to human MEC.
Methods: Newborn mouse submandibular glands (SMGs) were incubated with 1 × 105 PFU/ml of lacZ-tagged
mCMV RM427+ on day 0 for 24 hours and then cultured in virus-free media for a total of 6 or 12 days with or
without EGFR/ERK inhibitors and/or aciclovir. SMGs were collected for histology, immunolocalization (pERK, FN, IL-6),
viral distribution, or Western blot analysis (pERK).
Results: Here we report: (1) mouse SMG tumors soon exhibit an acquired resistance to EGFR/ERK pathway kinase
inhibitors, alone or in combination; (2) long term tumor regression can only be sustained by concurrent inhibitor
and antiviral treatment; (3) CMV-dependent, kinase inhibitor resistance is associated with overexpression of
fibronectin and IL-6 proteins in abnormal stromal cells.
Conclusions: Acquired resistance to kinase inhibitors is dependent upon CMV dysregulation of alternative
pathways with downstream effectors common with the targeted pathway, a phenomenon with important
therapeutic implications for human MEC of salivary glands.
Keywords: Cytomegalovirus, Salivary gland, Tumorigenesis, EGFR, ERK, Fibronectin, Interleukin 6Background
Mucoepidermoid carcinoma (MEC) is the most common
malignant tumor originating in major and minor salivary
glands (SGs), accounting for about 1/3 of all SG carcin-
omas [1,2]. Recently, we identified a relationship between
human cytomegalovirus (hCMV) and human SG MEC in
over 90% of cases; tumorigenesis in these cases uniformly
correlates with active hCMV protein expression and an* Correspondence: tjaskoll@usc.edu
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reproduction in any medium, provided the orupregulation and activation of the EGFR→ ERK pathway
[3]. Concomitant with this finding, we have developed a
novel mouse SG organ culture model of mouse CMV
(mCMV)-induced tumorigenesis that displays a number
of histologic and molecular characteristics similar to
human MEC [4-6]. Specifically, mCMV-induced SG
dysplasia/neoplasia is characterized by (1) mesenchymal-
to-epithelial transformation (MET); (2) epithelial islands
comprised of hyperplastic, dysplastic and neoplastic cells;
(3) an admixing of basophilic stromal and abnormal
epithelial cells; (4) migration of epithelial cells into dilated
ductal lumina; (5) de novo re-expression of CREB-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Melnick et al. Herpesviridae 2013, 4:1 Page 2 of 15
http://www.herpesviridae.org/content/4/1/1regulated transcription coactivator 1 (CRTC1) protein, a
protein found in SG MECs but not in normal SG tissue
[7]; and (6) an upregulation of the activated COX/AREG/
EGFR/ERK signaling pathway. Further, in the short term,
the mCMV-induced neoplastic phenotype can be partially
rescued by inhibitors of COX (diclofenac) and EGFR (gefi-
tinib), and fully rescued by an inhibitor of MEK1/2-
mediated ERK1/2 phosphorylation (U10126), as well as by
the antiviral, aciclovir.
Here we report that although EGFR/ERK pathway
inhibition initially attenuates tumor progression and
induces tumor regression, it is uniformly limited by an
acquired drug resistance, and subsequent failure to sus-
tain either tumor regression or stability. This drug resist-
ance appears to be dependent upon CMV dysregulation
of alternative pathways with downstream effectors com-
mon with the targeted pathway. These observations
likely have important therapeutic implications for
human salivary gland tumors.
Materials and methods
Animals
Timed pregnant inbred C57/BL6 female mice were pur-
chased from Charles River (Wilmington, MA) [plug day
= day 0 of gestation] and newborn (NB) mice were har-
vested as previously described [6,8]. All protocols involv-
ing mice were approved by the Institutional Animal
Care and Use Committee (USC, Los Angeles, CA).
Organ culture
Newborn (NB) SMGs were dissected and cultured for 6
(NB + 6) or 12 (NB + 12) days using a 3D organ culture
system and BGJb medium (Invitrogen Corporation,
Carlsbad, CA) as previously described [6]. This organ
culture system maintains the morphological integrity,
3D architecture and microenvironment associations
between acinar, ductal and stromal cells seen in in vivo
SMGs. Briefly, SMG organs were cultured on small discs
of Nucleopore filter (150 μm thick, with 0.8 μm pores),
which in turn were placed upon a stainless steel support-
ing grid (~15-25 filters per grid). The grids were then
placed on the inner ring of Grobstein culture dishes and
1 ml of medium was added to the well below the grid.
The SMG organs develop at the air/medium interface,
with the 1 × 105 plaque-forming units (PFU)/ml of lacZ-
tagged mCMV RM427+ [9] in BGJb medium being
below the grid on day 0 for 24 hrs and then with virus-
free medium with/without treatment for the remaining
culture period. Media with or without drugs was chan-
ged daily. SMG 3D organs were not “bathed in” mCMV-
infected medium as in cell and tissue culture systems,
exposed to virus-infected medium for the entire culture
period, nor inoculated with virus. Controls consisted of
SMG organs cultured in uninfected media. SMGs werecollected and processed for hematoxylin and eosin hist-
ology, immunolocalization, viral distribution or Western
blot analysis. For histology, and immmunolocalization
analysis, SMGs were fixed for 4 hours in Carnoy’s fixa-
tive at 4°C or overnight in 10% neutral buffered formalin
at room temperature, embedded in low melting point
paraplast, serially-sectioned at 8 μm and stained as pre-
viously described [6].
Recombinant virus: lacZ-tagged recombinant mCMV
RM427+ (kindly provided by Dr. Edward Mocarski) was
derived from murine CMV strain K181+ by insertion of
a lacZ expression cassette driven by a human CMV ie1/
ie2 gene promoter fragment [9]. To obtain a measure of
mCMV infection, we assayed for β-galactosidase (lacZ)
activity as previously described [6]. Briefly, NB + 6 and
NB + 12 SMGs were fixed in 0.2% gluteraldehyde in PBS
and stained for18 hrs at room temperature in standard
staining solution (5 mM potassium ferricyanide, 5 mM
potassium ferrocyanide, 2 mM MgCl2, 0.4% X-gal in
PBS). Whole mounts were then dehydrated through
graded alcohols, embedded in paraffin, serially-sectioned
at 8 μm and counterstained with eosin. β-galactosidase-
stained virus appears dark blue and uninfected cells ap-
pear pink.
Immunolocalization
Cultured SMG organs were embedded in low melting
point paraplast, serially-sectioned at 8 μm and immunos-
tained as previously described [6,8] using the following
commercially-available polyclonal antibodies: pERK1/2
(Thr202/Tyr204); IL-6 (Santa Cruz Biotechnology, Inc,
Santa Cruz, CA) and fibronectin (Sigma-Aldrich, St. Louis,
MO). Nuclei were counterstained with DAPI (Invitrogen
Corporation). Negative controls were performed in parallel
under identical conditions and consisted of sections incu-
bated without primary antibodies. For each treatment
group, 3–6 SMGs per day were analyzed. All images were
acquired with a Zeiss Axioplan microscope equipped with
a SPOT RT3 camera and processed with SPOT Advanced
and Adobe Photoshop CS2 software.
Western blot analysis
Uninfected (control), mCMV-infected, and GEF-treated
mCMV-infected NB + 6 SMGs were collected; each
independent sample consisted of 3–4 explants per
group. Proteins (25-35μg) were separated by SDS-PAGE
gels and transferred to a PVDF membrane, and the
membranes were subjected to chemiluminescence detec-
tion (ECL) according to the manufacturer’s instructions
(ThermoScientific, Rockford, IL) as previously described
[6]. Antibodies: pERK1/2 (Thr202/Tyr204) and β-actin
(Santa Cruz Biotechnology). Data was quantitated using
the ImageJ image analysis software (NIH) and normal-
ized to the level of β-actin expression in each sample.
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Significant differences between mCMV-infected and
control SMGs, as well as between mCMV and mCMV +
treatment SMGs, were determined by student t-test,
with α = 0.05 and the null hypothesis of R = 1. The cal-
culated expression ratios (Rs) were log or arcsin trans-
formed prior to analysis.Figure 1 Histologic morphology and cell-specific expression of fibron
analyses. F-H. Fibronectin (FN) immunolocalization. Control SMGs (A) are co
surrounded by fibromyxoid stroma. mCMV-infected SMGs (B-E) show signif
decrease in branched epithelia (e), hyperplastic and pseudostratified epithe
lacking a distinct BMZ and reduced cell-to-cell junctions, and there appears
cells (double black arrows). Abnormal epithelial islands are embedded in a
eosinophilic cells and large basophilic, pleiomorphic cells. Kidney-shaped n
in abnormal stromal and ductal cells. F-H. FN immunolocalization. Control
immunoreactivity at the BMZ (white arrow). In mCMV-infected SMGs (G-H)
surrounds individual metaplastic stromal cells (white arrowheads) and is ne
immunoreactivity is also seen filling ductal lumina. Bar: A-D, F-H- 50 μm; E-Interruption studies
We conducted 3 sets of interruption studies: (1) Targeting
of EGFR or ERK signaling: To target EGFR signaling, we
employed 10 μM gefitinib (GEF) (Selleck Chemicals LLC,
Houston, TX), a small molecule inhibitor which blocks the
binding of ATP to the intracellular TK domain of EGFR to
inhibit EGFR signaling, as described previously [5]. Toectin in control and mCMV-infected NB+12 SMGs. A-E. Histologic
mposed of densely packed, branched epithelial ducts and pro-acini (e)
icant viral CPE in the stroma and epithelial dysplasia. There is a notable
lial ducts with dilated lumina, abnormal multilayered epithelial islands
to be an admixing of the basophilic stromal and pro-acinar epithelial
hypercellular stroma (*) composed of 2 distinct cell types: small
uclei pathognomonic of mCMV infection (black arrowheads) are seen
SMGs (F) show a distinct and well-demarcated pattern of FN
, there is a marked shift in FN immunostaining: immunodetectable FN
arly absent from epithelial BMZ (double white arrows). FN
60 μm.
Figure 2 Histology and mCMV distribution in NB+6 and NB+12 control, mCMV-infected, GEF-treated, mCMV-infected, and U0126-
treated, mCMV-infected SMGs. A-H. NB + 6 SMGs. I-P. NB + 12 SMGs. Control SMGs (A, E) exhibit normal ductal and pro-acinar epithelia and
fibromyxoid stroma containing loosely-packed stellate to ovoid fibroblasts; note the absence of β-galactosidase staining (E, M). mCMV-infected
NB + 6 SMGs (B, F) exhibit stromal viral CPE in stroma, decreased epithelia with dilated lumina, and β-galactosidase-stained virus in peripheral stromal.
In GEF-treated, mCMV-infected NB + 6 SMGs (C, G), an improved phenotype consists of a fibromyxoid stroma, and decreased
β-galactosidase-stained virus. However, reduced epithelial branching and occasional viral CPE (double black arrowheads) persists. In U0126-treated,
mCMV-infected NB + 6 SMGs (D, H), the greatly improved phenotype approximates controls; these SMGs exhibit regularly branched epithelia, sparse
fibromyxoid stroma, and no ductal dilation or viral CPE; little β-galactosidase- is seen (H). I-P. NB + 12 SMGs. mCMV-infected NB + 12 SMGs (J, N) are
characterized by poorly-differentiated and dysplastic epithelia (arrows), abnormal stroma composed of sheets of small eosinophilic and larger
basophilic, pleiomorphic cells, some exhibiting pathognomonic kidney-shaped nuclei (arrowheads). And densely-packedβ-galactosidase-stained virus
throughout abnormal stroma and epithelia. GEF-treated, mCMV-infected SMGs (K, O) lost the improved phenotype seen on day 6 (compare K to C);
they exhibit epithelial dysplasia, viral CPE in the stroma, pathognomonic kidney-shaped nuclei (black arrowheads), and β-galactosidase staining
throughout abnormal stroma and sparsely in epithelia. U0126-treated, mCMV-infected SMGs (L, P) lost the improved phenotype seen on day 6, with
overt evidence of epithelial dysplasia, viral CPE, pathognomonic kidney-shaped nuclei (black arrowheads), and β-galactosidase-staining throughout
abnormal stroma and sparsely in epithelia. Reduced β-galactosidase staining is seen in GEF- and U0126-treated SMGs compared to untreated SMGs
(compare O, P to N). Bar: A-D, I-L - 50 μm; E-H, M-P- 40 μm.
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(EMD Chemicals, Inc, Gibbstown, NJ), a potent and
specific inhibitor of MEK-mediated ERK1 and ERK2 phos-
phorylation, as previously described [5]. These concentra-
tions were previously shown to be the optimal, nontoxic
dose that substantially precludes mCMV-induced path-
ology on day 6 of culture [5]. NB SMG organs were
infected with 1 × 105 PFU/ml mCMV for 24 hr in the
presence or absence of either 10 μM GEF or 10 μM
U0126 and then cultured in control medium + inhibitor
for a total of 6 or 12 days. Controls consisted of SMGs cul-
tured in control medium, 10 μM GEF-supplemented
media or 10 μM U0126-supplemented media. No differ-
ences were seen between untreated, GEF-treated, and
U0126-treated controls; we present untreated controls. (2)
Co-targeted inhibition of the EGF →ERK pathway: NBFigure 3 Spatial distribution of FN on days 6 and 12 of culture. A-D. N
distinct and well-demarcated pattern of FN immunoreactivity at the BMZ (w
localization in both NB + 6 (B) and NB + 12 (F) glands. FN immunostaining
with a notable decline in FN immunoreactivity at the BMZ being seen (dou
immunoreactivity is seen surrounding a small number of abnormal stroma
white arrows). In U0126-treated, mCMV-infected SMGs (D), FN is immunolo
seen in controls (compare D to A) and markedly different from that seen in
distribution of FN immunolocalization in GEF-treated (G) and U0126-treated
mCMV-infected SMGs (compare G, H to F); FN immunoreactivity shows a p
absence at the BMZ (double white arrows). Bar: A-B, D-H- 37 μm, C- 45 μmSMG organs were infected with 1 × 105 PFU/ml mCMV
for 24 hr in the presence or absence of either 10 μM GEF
or 10 μM U0126 and then in control medium + inhibitor.
Beginning on day 6, we additionally added either 10 μM
U1026 (GEF + D6U) or 10 μM GEF (U + D6 GEF) to the
culture medium for an additional 6 days; SMGs were cul-
tured for a total of 12 days (NB + 12). Controls consisted
of untreated, GEF + D6U-treated or U + D6 GEF-treated
SMGs. No differences between treatment groups were
seen; untreated controls are presented. (3) Dependency on
CMV: We used 10 μg/ml aciclovir sodium (American
Pharmaceutical Partners, Inc, Schaumberg, IL), a synthetic
purine nucleoside analogue which is a highly selective
agent for CMV with low toxicity to the host cell [10] and
previously shown to inhibit mCMV infection in mouse
SMGs in vitro [6]; this concentration was previouslyB + 6. E-H. NB + 12. Control NB + 6 (A) and NB + 12 (E) SMGs show a
hite arrows). In mCMV-infected SMGs, there is a marked change in FN
surrounds individual metaplastic stromal cells (white arrowheads),
ble white arrows). In GEF-treated, mCMV-infected NB + 6 SMGs (C), FN
l cells (white arrowheads) and is mostly absent from BMZ (double
calized at the BMZ (white arrow) in a pattern closely resembling that
untreated, mCMV-infected SMGs (compare D to B). In contrast, the
(H), mCMV-infected NB + 12 SMGs resembles that seen in untreated
ericellular distribution on stromal cells (white arrowheads) and near
.
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organs were infected with 1 × 105 PFU/ml mCMV in con-
trol medium, 10 μM GEF-supplemented medium or 10
μM U0126-supplemented medium for 24 hr and then in
control medium + inhibitor until day 6. Beginning on day
6, we added 10 μg/ml aciclovir to the medium (D6Acy; U
+ D6Acy; GEF + D6Acy) and cultured for an additional 6
days; SMGs were cultured for a total of 12 day (NB + 12).
Controls consisted of untreated, D6Acy, U + D6Acy-trea-
ted, or GEF + D6Acy-treated media. No differences be-
tween treatment groups were seen; untreated controls areFigure 4 Effect of EGFR/ERK inhibitors on the distribution of activated
NB + 6 SMGs. E-H. NB + 12 SMGs. mCMV induces a notable increase in pE
uninfected NB + 6 (A) and NB + 12 (E) controls (compare B to A and F to
show a notable decrease in immunodetectable pERK compared to untreat
pERK with U0126 treatment resembles that seen in controls (compare D to
GEF-treated (G) and U0126-treated (H) mCMV-infected SMGs compared to
resemblesuntreated, mCMV-infected SMGs seen on day 6 (compare G, H to
G- 60 μm.presented. For all in vitro studies, media was changed
daily; thus new drug treatments were added daily.
Results
The embracing paradigm of this line of investigation is
to identify molecular targets critical to altering pheno-
typic outcome as to preclude or treat human salivary
gland tumors, specifically those associated with active
CMV infection. To this end, we employ an in vitro sub-
mandibular salivary gland (SMG) 3D organ culture strat-
egy shown to induce cellular pathology which resemblesERK (pERK) in mCMV-infected NB + 6 and NB + 12 SMGs. A-D.
RK expression in NB + 6 (B) and NB + 12 (F) SMGs compared to
E). GEF-treated (C) and U0126-treated (D) mCMV-infected NB + 6 SMGs
ed mCMV-infected SMGs (compare C, D to B); the near absence of
A). By day 12, there is a marked increase in pERK expression in both
day 6 (compare G to C and H to D); pERK expression more closely
B) than to controls (compare G, H to E). Bar: A-F, H- 50 μm,
Figure 5 Western blot analysis of pERK protein expression in
mCMV-infected and GEF-treated, mCMV-infected NB + 6 and
NB + 12 SMGs. A. NB + 6 SMGs. B. NB + 12 SMGs. There is a
significant increase in pERK expression in GEF-treated, mCMV-infected
NB + 12 SMGs compared to identically treated NB + 6 SMGs (p<0.01;
n = 16). GEF treatment results in a significant decrease in pERK
expression in mCMV-infected NB + 6 SMGs compared to untreated
SMGs (p<0.01; n = 9), but no difference is seen between mCMV-
infected and GEF-treated, mCMV-infected NB + 12 SMGs (p>0.4; n = 9).
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ture system maintains the three-dimensional architec-
ture and microenvironment associations between acinar,
ductal and stromal cells seen in in vivo glands.
Newborn (NB) mouse SMG organs were cultured with
1 × 105 PFU/ml mCMV for 24 h and maintained for 6
or 12 days; controls consisted of NB SMG organs cul-
tured for identical periods in control medium. Control
SMGs (Figures 1A, 2A, I) demonstrate densely packed,
branched cuboidal epithelial cells within a sparse fibro-
myxoid stroma containing numerous stellate to ovoid
fibroblasts. The epithelia is composed of both serous
and mucous acini with associated ducts. Individual
epithelial cells have uniformly sized, centrally-located,
basophilic nuclei surrounded by eosinophilic cytoplasm.
Regularly distributed, small-diameter, centrally-located
ductal lumina are evident, often with pale staining
mucous. As expected, fibronectin (FN) is clearly evident
in the basement membrane zone (BMZ) of epithelial
ducts and acini (Figures 1F, 3A, E).
mCMV-infected NB + 6 and NB + 12 SMGs are char-
acterized by viral cytopathic effect (CPE) in the stroma
and abnormal parenchyma, altogether consistent with a
tumorigenic phenotype (Figures 1B-E, 2B, J). There is a
notable increase in mCMV infection between day 6 and
12 of culture (compare Figure 2N to 2F). On day 6,
mCMV initially infects peripherally-localized stromal
cells (Figure 2F); the absence of β-galactosidase-stained
virus in epithelia suggests that epithelial pathogenesis is
mediated by stromal-derived paracrine factors. By day
12, β-galactosidase-stained virus is densely distributed
throughout abnormal stroma, and in epithelial ductal
cells (Figure 2N). In mCMV-infected NB + 12 SMGs,
there is a marked increase in stromal cellularity and
abnormal epithelia compared to controls (compare
Figures 1B-E to A, 2J to I). The abnormal stroma is
composed of sheets of small eosinophilic cells and larger
basophilic, pleiomorphic cells. Individual stromal cells
are characterized by high nuclear-to-cytoplasm ratios,
prominent nuclei and nucleoli, and frequent kidney-
shaped nuclei pathognomonic of viral infection. In
addition, there is a dramatic decline in epithelial ductal and
acinar branching compared to controls; abnormal ducts
and acini are composed of hyperplastic or pseudostratified
epithelia and frequently exhibit severely dilated lumina.
Individual epithelial cells exhibit increased nuclear-to-
cytoplasm ratios, hyperchromatism, and visible nucleoli.
Importantly, epithelial cells exhibit a spectrum of morpho-
types, from dysplastic to in situ to invasive. Intra-luminal
and extra-basal proliferation and migration of epithelial
cells, lack of a distinct BMZ, and reduced cell-cell junc-
tions impart a multi-layered appearance to many of the
epithelial islands. Pyknosis, karyorrhexis and karyolytic
debris within lumina are also associated with some of theepithelial islands. Kidney-shaped nuclei pathognomonic of
CMV infection are frequently seen in stromal and ductal
epithelial cells (Figure 1C-E). Distinct from controls, FN
surrounds individual metaplastic stromal cells, and is rela-
tively absent from the BMZ of branched epithelia (com-
pare Figures 1G, H to F, 3B, F to 3A, E). Additionally,
immunodetectable pERK is seen in abundance (Figure 4B,
F), being absent in controls (Figure 4A, E).
Of particular concern here is the emerging resistance to
EGFR→ ERK pathway inhibitors (Figures 2, 3 and 4).
Gefitinib (GEF) blocks the binding of ATP to the intracel-
lular tyrosine kinase domain of EGFR and thus inhibits
downstream ERK 1/2 activation and cell proliferation, as
well as promotes cell cycle arrest at the G1–S boundary
and apoptosis [11,12]. In these studies, NB SMGs were
infected with 1 × 105 PFU/ml mCMV for 24 hrs in the
presence or absence of 10 μM GEF and then cultured in
control medium with or without GEF for a total of 6 or 12
days. As previously reported [5], after 6 days in culture
(NB + 6), mCMV-infected, GEF-treated SMGs present a
much improved phenotype (Figures 2C, 3C). There is a
marked increase in normal epithelial branching, and no
ductal dilation. FN immunostaining is seen in a subset of
epithelial BMZ and on stromal cells; FN is also absent
from a subset of epithelial BMZs (Figure 3C). There is
predominantly a fibromyxoid stroma containing stellate
fibroblasts, and only occasional viral CPE. This “near
rescue” of the mCMV-induced pathology of NB + 6 SMGs
with GEF inhibition of EGFR phosphorylation is coinci-
dent with reduced mCMV infection compared to un-
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highly significant (p<0.01) decline in downstream pERK
protein expression (compare Figure 4C to B; Figure 5A).
After 12 days in culture (NB + 12), mCMV-infected,
GEF-treated SMGs present a regressive phenotype with
overt evidence of epithelia dysplasia, viral CPE in the
stroma (Figures 2J, 3G, 4G), and a notable increase in
mCMV infection throughout stroma compared to day 6
(compare Figure 2O to G). Epithelial branching is mark-
edly reduced, ductal lumina are frequently dilated, and
individual epithelial cells have increased nuclear-to-
cytoplasmic ratios, hyperchromatism, and visible nucleoli.Figure 6 Effect of co-targeting pathways on histopathology in mCMV
mCMV-infected SMGs (B) show pathology composed of abnormal epithelia
treated with U0126 beginning on day 6 (CMV + GEF + D6U) (C) exhibit pro
stromal pathology with viral CPE (arrowhead) (compare C to B). Inset: High
treated, mCMV-infected SMGs treated with GEF beginning on day 6 (CMV
improved epithelial morphology and branching (compare D to B, C), with
A). Inset: Higher magnification of mCMV-infected and affected stromal cells
on day 6 (CMV + GEF + D6 Acy) demonstrate a near normal morphology o
fibromyxoid stroma (compare E to A). Right Inset: Higher magnification of
acini. U0126-treated, mCMV-infected SMG (F) treated with aciclovir beginni
morphology, composed of a highly branched epithelia in a fibromyxoid str
magnification of stromal stellate fibroblasts. Bar: A-F, 50 μm; Insets C, D, F -The stroma contains sheets of small eosinophilic and
large, basophilic, pleiomorphic cells with high nuclear-to-
cytoplasmic ratios, prominent nuclei and nucleoli and
frequent pathognomonic kidney-shaped nuclei. Again, FN
surrounds individual metaplastic stromal cells and is rela-
tively absent from the BMZ of epithelia (Figure 3G). By
day 12, there is a marked increase in pERK protein expres-
sion in GEF-treated, mCMV-infected SMGs relative to
day 6 (p<0.01); by day 12, there is no significant difference
(p>0.4) between GEF-treated and non-treated mCMV-
infected SMGs (compare Figure 4G to C, G to F;
Figure 5).-infected NB + 12 SMGs. A. Control SMG. B-F. mCMV-infected SMGs.
and viral CPE in the stroma. GEF-treated, mCMV-infected SMGs
gressive pathology but continues to present decreased branching and
er magnification of mCMV-infected and affected stromal cells. U0126-
+ U + D6 GEF) (D) exhibit progressive pathology and demonstrates
continued viral CPE in stroma (arrowhead) being seen (compare D to
. GEF-treated, mCMV-infected SMG (E) treated with aciclovir beginning
f extensive epithelial branching, abundant serous acini, and a
stromal stellate fibroblasts. Left Inset: Higher magnification of serous
ng on day 6 (CMV + U + D6 Acy) demonstrate a near normal
oma approximating control SMGs (compare F to A). Inset: Higher
25 μm. E, left inset- 30 μm; right inset - 25 μm.
Figure 7 The effects of co-targeting pathways on viral distribution in NB + 12 SMGs. In control SMGs (A), uninfected epithelia and stroma
appear pink. In mCMV-infected SMGs (B), densely-packed β-galactosidase-stained virus is seen thoughout stroma and in epithelial duct cells. In
GEF-treated, mCMV-infected SMGs treated with U0126 beginning on day 6 (C), there is a reduction in β-galactosidase-stained virus in stroma and
a more notable reduction in epithelia compared to untreated SMGs (compare C to B). In U0126-treated, mCMV-infected SMGs treated with GEF
beginning on day 6 (D), there is a greater reduction in β-galactosidase-stained virus than seen in SMGs initially treated with GEF (compare D to
C). Addition of aciclovir beginning on day 6 to GEF-treated, mCMV-infected SMGs (E) and U0126-treated, mCMV-infected SMGs (F) results in the
near absense of β-galactosidase-stained virus. Bar: A-C, E-F, 50 μm; D 60 μm.
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signaling pathways other than EGFR might explain the
incomplete GEF-mediated rescue of mCMV-induced
pathology in NB + 6 SMG organs [5]. We tested this
hypothesis by direct inhibition of ERK activation using
U0126, a small molecule inhibitor of MEK-mediated
ERK phosphorylation (e.g. [13]). In these experiments,
NB SMGs were infected with 1 × 105 PFU/ml mCMV
for 24 hrs in the presence or absence of 10 μM U0126
and then cultured in control medium with or without
U0126 for a total of 6 or 12 days. As previously reported
[5], U0126-treated, mCMV-infected NB + 6 SMGs are in-
distinguishable from controls (compare Figure 2D to A):
normal branching epithelia, no ductal dilation, sparse
fibromyxoid stroma, FN immunolocalized to epithelial
BMZ, and no evidence of pERK protein expression
(Figures 3D, 4D). This rescue is likely due to the near ab-
sence of mCMV infection (Figure 2H). Nevertheless, by
NB + 12, mCMV-infected, U0126-treated SMGs present a
metaplastic phenotype not unlike that seen with GEFFigure 8 The effects of co-targeting pathways on FN distribution in N
pattern of FN immunoreactivity at the BMZ (white arrow). B-F. mCMV-infec
surrounding abnormal stromal cells (white arrowheads) but is relatively abs
infected SMGs treated with U0126 beginning on day 6 (C), FN immunostai
is mostly absent from BMZ (double white arrows); FN is sporadically seen in
with GEF beginning on day 6 (D), FN is immunolocalized both at the BMZ
arrowheads) but is absent from the BMZ of a subset of epithelial islands (d
6 to GEF-treated, mCMV-infected SMGs (E) or U0126-treated, mCMV-infecte
is primarily seen at the BMZ (white arrow) in a pattern resembling that seetreatment on day 12, even if less severe, including a
marked upregulation of pERK protein expression compared
to day 6 (Figures 2L, 3H, 4H). mCMV burden is similar to
that seen in GEF-treated NB + 12 SMGs (compare
Figure 2P to O) and notably more than on day 6 (compare
Figure 2P to H).
Co-targeted inhibition of the EGF → ERK pathway
Tyrosine autophosphorylation of the intracellular do-
main of EGFR results in the recruitment of the GRB2/
SOS signaling complex, GTP-loading of the proximate
Ras, and subsequent activation of Raf kinase and a phos-
phorylation cascade from MEK to ERK. Importantly, the
ERK pathway resembles a negative feedback amplifier
(NFA) with the amplifier consisting of the three-tiered
kinase module Raf-MEK-ERK and negative feedbacks
emanating from ERK to SOS and Raf; the ratio of
protein abundances of Raf, MEK and ERK is about 1:3:6
[13]. This NFA is much like similar design principles
used in electronic circuits to confer robustness, outputB + 12 SMGs. Control SMGs (A) show a distinct and well-demarcated
ted SMGs. In mCMV-infected SMGs (B), FN immunoreactivity is found
ent at the epithelial BMZ (double white arrow). In GEF-treated, mCMV-
ning is primarily seen surrounding stromal cells (white arrowhead) and
BMZ (white arrow). In U0126-treated, mCMV-infected SMGs treated
(white arrow) and surrounding abnormal stromal cells (white
ouble white arrows). The addition of aciclovir treatment beginning day
d SMGs (F) results in a more normal staining pattern; FN immunostain
n in controls (compare E, F to A). Bar: 38 μm.
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lification [13]. These properties are determinative of
both activation kinetics and response to small molecule
inhibitors. Having already established that there is fairly
rapid resistance to individual inhibitors of nodes out-
side (EGFR/gefitinib) and inside (MEK/U0126) the NFA
(Figures 2, 3, 4 and 5), we needed to delineate an alter-
native strategy to break the NFA. To preclude resistance
in the long-term, modeling and cell culture studies have
suggested concurrently inhibiting targets outside and in-
side the NFA [13,14].
In these studies, NB SMGs are infected with 1 × 105
PFU/ml mCMV for 24 hr in the presence of either 10
μM GEF or 10 μM U0126 and then cultured to day 12 in
control medium with the respective inhibitor along with
the addition of either 10 μM U1026 (GEF + D6U) or 10
μM GEF beginning on day 6 (U + D6GEF). GEF-treated,
mCMV-infected SMGs co-treated beginning on day 6
with U0126 demonstrate morphologic improvement with-
out ductal dilation (compare Figure 6C to B), but there isFigure 9 The effects of co-targeting pathways on the spatial expressi
immunostaining is mostly absent. mCMV-infected SMGs (B) are characterize
(arrowheads) compared to control (compare B to A). In GEF-treated, mCMV
treated, mCMV-infected SMGs treated with GEF beginning on day 6 (D), pE
D to A). The addition of aciclovir treatment beginning on day 6 to GEF-tre
near absence of pERK immunoreactivity which closely resembles controls (continued evidence of decreased epithelial branching and
stromal pathology with viral CPE (compare Figure 6C to
A). This improvement is coincident with reduced mCMV
burden compared to untreated SMGs (compare
Figure 7C to B). FN is still primarily seen surrounding
stromal cells (Figure 8C); pERK continues to be expressed
at high levels (Figure 9C). For U0126-treated, mCMV-
infected SMGs co-treated beginning on day 6 with GEF,
the morphological phenotype and viral load are similar to
that seen in GEF + D6 U0126 treated NB + 12 SMGs
(compare Figure 6D to C, Figure 7D to C). Interesting dif-
ferences include increased epithelial branching (compare
Figure 6D to C) with the reappearance of FN at the BMZ
of acini and ducts along with surrounding abnormal stro-
mal cells (Figure 8D), and a marginally diminished pERK
protein expression (Figure 9D). Thus, though the rescue is
incomplete, co-targeted inhibition of the EGFR →ERK
pathway precludes the regression to the more severe path-
ology seen with single-targeted inhibition (compare 6C to
2k and 6D to 2L).on of pERK in NB + 12 SMGs. In control SMGs (A), pERK
d by a marked increase in pERK expression in stromal cells
-infected SMGs treated with U0126 beginning on day 6 (C) or U0126-
RK immunoreactivity is seen in stromal cells (arrowheads) (compare C,
ated SMGs (E) or U0126-treated, mCMV-infected SMGs (F) results in the
compare E, F to A). Bar: A-B, E-F- 50 μm; C-D- 55 μm.
Figure 10 mCMV-induced changes in the spatial distribution of
IL-6 on days 6 and 12 of culture. A-D. NB + 6 SMGs. E-H. NB + 12
SMGs. In controls (A, E), IL-6 immunostain is weakly seen on ductal
and proacinar epithelia (e); it is also localized in nerves (arrows). With
mCMV infection (B, F), there is a marked increase in
immunodetectable IL-6 in abnormal stromal cells (arrowheads) but is
relative absent from epithelia. Insets: Higher magnification of IL-6
stained stromal cells. In GEF-treated, mCMV-infected NB + 6 SMGs
(C), IL-6 immunoreactivity is seen primarily on stromal cells
(arrowheads). In U0126-treated, mCMV-infected NB + 6 SMGs (D),
IL-6 immunostaining resembles that seen in controls; IL-6 is weakly
seen on epithelia (e) but absent from stroma (s). On day 12,
GEF-treated, mCMV-infected (G) or U0126, mCMV-infected (H) SMGs
exhibit IL-6 immunoreactivity throughout the stromal cells (black
arrowheads) and absence from epithelia. Bar: 50μm; Insets
B, F -30 μm.
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The extensive effort to identify resistance mechanisms
has uncovered a recurrent theme, namely the utilization
of survival signals redundant to those transduced by the
targeted kinase or kinase pathway [15,16]. CMV has
evolved numerous strategies for dysregulating host cell
signaling in order to propagate viral progeny [6,17]. Fur-
ther, we have previously shown that when SMGs in vitro
are infected with mCMV for 24 h and then cultured for
6–12 days in the presence of the antiherpesviral nucleo-
side, aciclovir, mCMV replication is suppressed and the
SMGs are histologically and molecularly normal [4-6].
Thus, we tested the hypothesis that addition of aciclovir
beginning on day 6, along with the EGFR/ERK pathway
inhibitor, would preclude progressive pathway dysregula-
tion and rescue the infected NB SMGs.
In these experiments, NB SMGs were infected with
1 × 105 PFU/ml mCMV for 24 h in the presence of
either 10 μM GEF or 10 μM U0126 and then cultured to
day 12 in control medium with the respective inhibitor
along with the addition of 10 μg/ml aciclovir beginning
on day 6 (CMV + GEF + D6Acy; CMV + U0126 + D6
Acy). GEF-treated, mCMV-infected SMGs treated with
aciclovir beginning on day 6 show normal epithelial
branching and normal fibromyxoid stroma (Figure 6E),
as well as the near absence of β-galactosidase-stained
virus (Figure 7E). The distribution patterns of FN and
pERK are similar to controls; FN is localized to the BMZ
of epithelia and there is no detectable pERK protein ex-
pression (compare Figures 8E to A, 9E to A). The results
of U0126-treated SMGs with aciclovir beginning on day
6 are identical (Figures 6F, 7F, 8F, 9F). Clearly the main-
tenance of SMG pathology is dependent upon (“addicted
to,” if you will) active and robust viral replication
(Figures 2M-P, 7), expression of late viral gene products,
and the concomitant subversion of multiple host cell
signaling pathways.
Gene expression profiles of a limited number (n = 6)
of human SG MEC specimens have revealed a significant
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We have previously found that mCMV induced patho-
genesis in embryonic mouse SMGs is characterized by
the upregulation of several major ERK 1/2 related path-
ways in addition to EGFR, including FN and IL-6 [6].
Here we examined both FN and IL-6 protein cell-
specific distribution relative to the mCMV-induced
pathologic phenotype in NB SMGs.
We have shown above that mCMV infection of NB
SMGs dysregulates FN protein expression on days 6 and
12 of culture, namely upregulation and cytologic redis-
tribution (Figures 3A, B, E, F; 8A, B). This is somewhat
ameliorated by day 6 with GEF treatment (Figure 3C)
and eliminated with U0126 treatment (Figure 3D). How-
ever, only the addition of the antiviral, aciclovir, beginning
on day 6 of culture, precludes progressive FN dysregula-
tion, and effects concomitant rescue of infected NB SMGs
by day 12 (compare Figures 8E, F to 3G, H).
With respect to IL-6, mCMV infection of NB SMGs
through day 12 of culture is associated with both overex-
pression and redistribution of IL-6 protein from epithelia
to abnormal stromal cells (compare Figure 10B, F to A, E).
In GEF-treated SMGs, the pathology seen on day 6 of cul-
ture is concomitant with overexpression and localization
of IL-6 to the abnormal stromal cells (Figure 10C). In con-
trast, U0126-treated, mCMV-infected NB + 6 SMGs ex-
hibit a localization pattern similar to that seen in controls
(compare Figure 10D to A). In all treatment groups (GEF;
U0126; GEF + D6U0126; U0126 + D6GEF), the pathology
seen on day 12 of culture is concomitant with overexpres-
sion and localization of IL-6 to the abnormal stromal cells,
with a slightly improved localization pattern being seen
with pathway co-targeting (Figures 10G-H, 11E-F). Only
the addition of aciclovir beginning on day 6 to either GEF
(GEF + D6Acy) or U0126 (U + D6Acy) precludes progres-
sive IL-6 dysregulation, and effects concomitant rescue of
infected NB SMGs by day 12 of culture (Figure 11C, D).
Aciclovir treatment alone results in a somewhat improved
IL-6 distribution pattern, with IL-6 being seen on fewer
stromal cells than in untreated, mCMV-infected SMGs
(compare Figure 11B to A).Figure 11 The effects of antivirals with/without co-targeting
the EGFR/ERK pathway on IL-6 protein expression in NB + 12
SMGs. mCMV infection (A) induces a notable increase in
immunodetectable IL-6 in abnormal stromal cells. The addition of
aciclovir beginning on day 6 (CMV + D6 Acy) (B) substantially
reduces IL-6 immunostaining in stroma. When aciclovir was added
beginning on day 6 to U0126-treated (CMV + U + D6 Acy) (C) or
GEF-treated (CMV + GEF + D6Acy) (D) SMGs, the distribution of IL-6
immunostaining resembles control (compare C, D to 10 A, E), being
detected in epithelia (e) and nerve cells (arrow) and absent from
stroma. In contrast, IL-6 immunolocalization persists in stromal cells
(arrowheads) in both U0126-treated SMGs treated with GEF
beginning on day 6 (CMV + U + D6GEF) (E) or GEF-treated SMGs
treated with U0126 beginning on day 6 (CMV+ GEF+ D6U) (F).
Bar: A, B, F- 40 μm; C-E - 50 μm.Discussion
As one element of a certain multifactorial etiology, we
recently identified a virally implicated relationship be-
tween active human CMV and mucoepidermoid carcin-
oma of the human salivary glands [3]. More than 90% of
MEC specimens uniformly correlate with active hCMV
protein expression and an upregulation and activation of
the EGFR →ERK pathway. Even though targeting this
pathway would appear to be a good therapeutic ap-
proach, human trials with small molecule protein kinase
inhibitors (PKIs) have met with limited initial success,increasing drug resistance and subsequent progressive
tumorigenesis [15,19,20].
Using a mouse 3D organ culture model of CMV-
induced cellular pathology which resembles secretory
glandular neoplasia [4,5], we have identified several
emergent phenomena that are likely dispositive clues to
the mechanism of resistance: (1) while there is short
Melnick et al. Herpesviridae 2013, 4:1 Page 14 of 15
http://www.herpesviridae.org/content/4/1/1term rescue, mouse SMGs tumors soon reveal an
acquired resistance to EGFR → ERK pathway protein
kinase inhibitors (PKIs), alone or in combination; (2)
SMG neoplasia is dependent upon the continued activity
of CMV (“viral addiction”) and, thus, long term tumor
regression can only be sustained by concurrent PKI and
antiviral treatment; (3) CMV-dependent, PKI resistance
is associated with ectopic overexpression of FN and IL-6
proteins in abnormal stromal cells. These observations
may have important therapeutic implications for human
salivary gland tumors.
Two key resistance mechanisms appear to be increased
expression/activation of the targeted kinase, and use of
alternative signaling to activate downstream cell survival
pathways [15]. More specifically, tumor cells typically
upregulate multiple pathways that mediate signals which
share common critical downstream effectors, particularly
PI3K/AKT and MEK/ERK transduction [16]. IL-6/IL-6R
and FN/integrin binding initiate multifunctional signaling
(PI3K/AKT and MEK/ERK) that mediates cell growth,
differentiation and survival in development and progres-
sive tumorigenesis [21-25]. Further, there is mutual cross-
talk between FN/integrin and EGFR [26]. It would appear,
then, that CMV-dependent FN and IL-6 overexpression in
abnormal stromal cells increases the activation of the
targeted kinase, ERK (Figures 3, 4, 8, 9, 11) and likely
induces alternative signaling (e.g. PI3K/AKT; FN/INT/
EGFR). Thus, in the presence of active CMV (Figures 2O,
P, 7C, D), even the highest nontoxic dose of MEK→ ERK
inhibitor (U0126) is unable to preclude progressive
tumorigenesis (Figure 2L), nor is the highest dose of EGFR
inhibitor (GEF) (Figure 2K) or combination of inhibitors
(Figure 6C, D).
These results permit a glimpse of the complexity before
us. Given the considerable pathway crosstalk and redun-
dancy in mammalian cells and the multifunctional paths
mediated by single molecular components, elucidating the
precise effect of a virus on the host “interactome” is quite
daunting [27]. Nevertheless, systematic analyses of host
targets can identify dysregulated host cell networks and
potentially reveal all pathways that go awry in virally
implicated tumorigenesis [28]. Ultimately, it is a problem
amenable to quantitative systems analysis, not unlike
those in embryonic development and differentiation [8].
Conclusions
We report that although EGFR → ERK pathway inhib-
ition initially attenuates tumor progression and induces
tumor regression, it is uniformly limited by an acquired
drug resistance, and subsequent failure to sustain either
tumor regression or stability. Long term tumor regres-
sion can only be sustained by concurrent kinase inhibi-
tor and antiviral treatment. The resistance to kinase
inhibitors is dependent upon CMV dysregulation ofalternative pathways with downstream effectors common
with the targeted pathway, a phenomenon with import-
ant therapeutic implications for human MEC of salivary
glands.
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